Trial Profile
Prospective and randomized study on the efficacy of novel hypoglycemic type 2 diabetes agent ipragliflozin to serum glycemic control and cardiovascular risk factors
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 18 May 2016
Price :
$35
*
At a glance
- Drugs Ipragliflozin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Pharmacodynamics
- 01 Jul 2015 Status changed from recruiting to completed as per University Hospital Medical Information Network - Japan.
- 15 Aug 2014 Status changed from not yet recruiting to recruiting as reported by University Hospital Medical Information Network - Japan
- 18 Jul 2014 New trial record